Atossa Therapeutics (ATOS) Research & Development (2012 - 2026)
Atossa Therapeutics' Research & Development was $4.9 million in Q2 2026, down 11.0% from $5.5 million a year earlier but up 2.5% from the prior quarter.
Powered by 
Analysis
Atossa Therapeutics (ATOS) Research & Development (2012 - 2026) Analysis & Trends
On a trailing twelve-month basis, Atossa Therapeutics' Research & Development was $21.2 million through Jun 30, 2026, up 28.7% year-over-year; for FY2025, it was $21.19 million, up 50.1% from FY2024.
- Research & Development shows a five-year compound annual growth rate of 26.2% (FY2020 to FY2025).
- In earlier years, Research & Development was $14.12 million in FY2024 (-18.6%), $17.33 million in FY2023 (+14.9%), $15.08 million in FY2022 (+63.8%) and $9.21 million in FY2021 (+39.4%).
- Quarterly Research & Development has moved between $1.5 million (Q1 2022) and $6.16 million (Q4 2025) over five years.
- Compared with a year earlier, Research & Development was higher in five of the last eight quarters, with growth averaging 18.1%.
- The best year-over-year quarter for Research & Development over five years was Q4 2022 (growth of 172.9%); the worst was Q4 2024 (a decline of 39.8%).
- Per Business Quant data, ATOS's Research & Development in the three quarters before Q2 2026 was $4.78 million (Q1 2026), $6.16 million (Q4 2025) and $5.37 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 3.02 Bn |
| 10 | Atossa Therapeutics | 19.96 Mn | -131.01 Mn | - | 4.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.90 Mn |
| Mar 31, 2026 | 4.78 Mn |
| Dec 31, 2025 | 6.16 Mn |
| Sep 30, 2025 | 5.37 Mn |
| Jun 30, 2025 | 5.50 Mn |
| Mar 31, 2025 | 4.16 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 3.55 Mn |
| Mar 31, 2024 | 3.75 Mn |
| Dec 31, 2023 | 5.65 Mn |
| Sep 30, 2023 | 4.47 Mn |
| Jun 30, 2023 | 3.71 Mn |
| Mar 31, 2023 | 3.51 Mn |
| Dec 31, 2022 | 4.99 Mn |
| Sep 30, 2022 | 5.16 Mn |
| Jun 30, 2022 | 3.43 Mn |
| Mar 31, 2022 | 1.50 Mn |
| Dec 31, 2021 | 1.83 Mn |
| Sep 30, 2021 | 2.21 Mn |
API Access
Atossa Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ATOS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ATOS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ATOS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();